Forecasting The Future: 13 Analyst Projections For Avidity Biosciences

Benzinga18:00 ET

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025

BenzingaMar 17 13:48 ET

Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target

BenzingaMar 17 12:58 ET · Ratings

Avidity Biosciences Analyst Ratings

BenzingaMar 17 10:05 ET · Ratings

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

BenzingaMar 16 10:40 ET

PTC Therapeutics Analyst Ratings

BenzingaMar 14 10:46 ET · Ratings